{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:11:51Z","timestamp":1793711511667,"version":"4.6.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejps.2025.107057","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:25:21Z","timestamp":1741001121000},"page":"107057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma"],"prefix":"10.1016","volume":"208","author":[{"given":"Nasreddine","family":"El Omari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Bakrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Elhrech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Aanniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaali","family":"Balahbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Learn-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Abdulmonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Bouyahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107057_bib0001","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V128.22.3298.3298","article-title":"Synergistic anti-tumor effect of KPT-8602, a second generation selective inhibitor of nuclear export (SINE) compound, and panobinostat, a pan-histone deacetylase (HDAC) inhibitor in multiple myeloma","volume":"128","author":"Argueta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107057_bib0002","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2025.107057_bib0003","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejps.2025.107057_bib0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0609.2009.01384.x","article-title":"Vorinostat enhances the antimyeloma effects of melphalan and bortezomib","volume":"84","author":"Campbell","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13578-017-0188-9","article-title":"Tumorigenesis as a process of gradual loss of original cell identity and gain of properties of neural precursor\/progenitor cells","volume":"7","author":"Cao","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejps.2025.107057_bib0006","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2025.107057_bib0007","article-title":"Recent update of HDAC inhibitors in lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejps.2025.107057_bib0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/or.2013.2913","article-title":"Epigenetic regulation and cancer (Review)","volume":"31","author":"Chen","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejps.2025.107057_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1341031","article-title":"Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejps.2025.107057_bib0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0011","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15384047.2016.1219820","article-title":"The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines","volume":"17","author":"Cosenza","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejps.2025.107057_bib0012","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejps.2025.107057_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114049","article-title":"Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics","volume":"229","author":"Cui","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2025.107057_bib0014","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.3390\/cancers12103037","article-title":"Epstein\u2013Barr virus promotes B cell lymphomas by manipulating the host epigenetic machinery","volume":"12","author":"Di Pietro","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107057_bib0015","doi-asserted-by":"crossref","first-page":"28586","DOI":"10.18632\/oncotarget.25580","article-title":"The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma","volume":"9","author":"Dias","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2025.107057_bib0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.vetimm.2013.05.004","article-title":"Epigenetic regulation of the innate immune response to LPS in bovine peripheral blood mononuclear cells (PBMC)","volume":"154","author":"Doherty","year":"2013","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.ejps.2025.107057_bib0017","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejps.2025.107057_bib0018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/leu.2008.12","article-title":"Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype","volume":"22","author":"Ehlers","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2025.107057_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114886","article-title":"Molecular mechanisms underlying the clinical efficacy of panobinostat involve stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses","volume":"164","author":"El Omari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107057_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115212","article-title":"Anticancer clinical efficiency and stochastic mechanisms of belinostat","volume":"165","author":"El Omari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107057_bib0021","doi-asserted-by":"crossref","first-page":"e33052","DOI":"10.1016\/j.heliyon.2024.e33052","article-title":"Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat","volume":"10","author":"El Omari","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejps.2025.107057_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114774","article-title":"Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin","volume":"164","author":"El Omari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107057_bib0023","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0024","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/1538-7445.AM2016-4720","article-title":"Synergistic antitumor effect of selinexor, a selective inhibitor of nuclear export (SINE) compound and panobinostat in a mouse model of multiple myeloma","volume":"76","author":"Elloul","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0025","doi-asserted-by":"crossref","first-page":"37280","DOI":"10.18632\/oncotarget.26460","article-title":"Predictive biomarkers for disease sensitivity in lymphoma\u2013the holy grail for HDAC inhibitors?","volume":"9","author":"Eyre","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2025.107057_bib0026","doi-asserted-by":"crossref","unstructured":"Fenichel, M.P., 2015. FDA approves new agent for multiple myeloma.","DOI":"10.1093\/jnci\/djv165"},{"key":"10.1016\/j.ejps.2025.107057_bib0027","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/10428194.2015.1063143","article-title":"Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells","volume":"57","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejps.2025.107057_bib0028","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0029","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2217\/fon-2018-0881","article-title":"Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia","volume":"15","author":"Frustaci","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0031","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0032","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2009.07887.x","article-title":"Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors","volume":"147","author":"Gloghini","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0033","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1078-0432.CCR-13-1576","article-title":"Reducing TNF receptor 2+ regulatory T cells via the combined action of Azacitidine and the HDAC inhibitor, Panobinostat for clinical benefit in acute myeloid leukemia patients","volume":"20","author":"Govindaraj","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0034","doi-asserted-by":"crossref","unstructured":"Green, M.R., Gentles, A.J., Nair, R.V., Irish, J.M., Kihira, S., Liu, C.L., Kela, I., Hopmans, E.S., Myklebust, J.H., Ji, H., Plevritis, S.K., Levy, R., Alizadeh, A.A., 2013. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.","DOI":"10.1182\/blood-2012-09-457283"},{"key":"10.1016\/j.ejps.2025.107057_bib0035","series-title":"Histone Deacetylases: The Biology and Clinical Implication, Handbook of Experimental Pharmacology","first-page":"13","article-title":"The biology of HDAC in cancer: the nuclear and epigenetic components","author":"Hagelkruys","year":"2011"},{"key":"10.1016\/j.ejps.2025.107057_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106824","article-title":"Mantle cell lymphoma and the evidence of an immature lymphoid component","volume":"115","author":"Hansen","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0037","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00018-010-0624-z","article-title":"Epigenetic aberrations during oncogenesis","volume":"68","author":"Hatziapostolou","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejps.2025.107057_bib0038","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/15384047.2016.1250046","article-title":"Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma","volume":"17","author":"Havas","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejps.2025.107057_bib0039","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/blood.V116.21.3936.3936","article-title":"Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the anti-tumor activity of Bortezomib (BTZ) In Rituximab-chemotherapy sensitive and resistant lymphoma cell lines","volume":"116","author":"Hernandez-Ilizaliturri","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107057_bib0040","unstructured":"Herrera-Mart\u00ednez, M., Orozco-Samperio, E., Monta\u00f1o, S., Ariza-Ortega, J.A., Flores-Garc\u00eda, Y., L\u00f3pez-Contreras, L., 2020. Vorinostat as potential antiparasitic drug."},{"key":"10.1016\/j.ejps.2025.107057_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejps.2025.107057_bib0042","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107057_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/hon.56_2879","article-title":"The combination of Duvelisib and Romidepsin (DR) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8797206","article-title":"HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases","volume":"2016","author":"Hull","year":"2016","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejps.2025.107057_bib0045","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.18632\/oncotarget.26726","article-title":"PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-\u03b3","volume":"10","author":"Iwasa","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2025.107057_bib0046","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of Pralatrexate and Romidepsin confirms potent synergy of the combination in a murine model of Human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0047","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/17474086.2020.1756257","article-title":"Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"13","author":"Jennifer","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0048","doi-asserted-by":"crossref","first-page":"12371","DOI":"10.3390\/ijms222212371","volume":"22","author":"Jurutka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107057_bib0049","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7243\/2050-0874-2-2","article-title":"HDAC inhibitors: applications in oncology and beyond","volume":"2","author":"Katoch","year":"2013","journal-title":"HOAJ Biol."},{"key":"10.1016\/j.ejps.2025.107057_bib0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.23112","article-title":"The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients","volume":"87","author":"Kelly-Sell","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0051","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/thoraxjnl-2014-206411","article-title":"Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis","volume":"70","author":"Korfei","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.ejps.2025.107057_bib0052","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1155\/2006\/760183","article-title":"Acetylation and histone deacetylase inhibitors in cancer","volume":"28","author":"Kortenhorst","year":"2006","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.ejps.2025.107057_bib0053","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejps.2025.107057_bib0054","doi-asserted-by":"crossref","first-page":"e83160","DOI":"10.1371\/journal.pone.0083160","article-title":"Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejps.2025.107057_bib0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2015.06.145","article-title":"The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells","volume":"464","author":"Lu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2025.107057_bib0056","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-09-3174","article-title":"Synergistic killing effect between vorinostat and target of CD146 in malignant cells","volume":"16","author":"Ma","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0057","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15548627.2016.1269988","article-title":"MTORC1-mediated NRBF2 phosphorylation functions as a switch for the class III PtdIns3K and autophagy","volume":"13","author":"Ma","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.ejps.2025.107057_bib0058","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.rcl.2008.03.005","article-title":"Overview of lymphoma diagnosis and management","volume":"46","author":"Matasar","year":"2008","journal-title":"Radiol. Clin. N. Am."},{"key":"10.1016\/j.ejps.2025.107057_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108114","article-title":"The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies","volume":"100","author":"Mehrpouri","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejps.2025.107057_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173050","article-title":"Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: shedding light on mitigating effects of NF-\u03baB and autophagy on panobinostat cytotoxicity","volume":"875","author":"Mehrpouri","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107057_bib0061","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Mehta-Shah","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0062","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1182\/blood.V118.21.3621.3621","article-title":"Synergistic effect of Panobinostat and Bortezomib on chemoresistant acute myelogenous leukemia cells via Akt\/NF-\u03baB pathway","volume":"118","author":"Meng","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107057_bib0063","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12032-022-01813-w","article-title":"Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t (4; 11) but promotes antagonistic effects in combination with MTX and 6MP","volume":"39","author":"Moreno","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0064","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s10637-011-9751-0","article-title":"Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors","volume":"30","author":"Morita","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejps.2025.107057_bib0065","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/nature04956","article-title":"Asymmetric and symmetric stem-cell divisions in development and cancer","volume":"441","author":"Morrison","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2025.107057_bib0066","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10637-015-0206-x","article-title":"Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia","volume":"33","author":"Morschhauser","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejps.2025.107057_bib0067","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10637-012-9831-9","article-title":"Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines","volume":"31","author":"Muscal","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejps.2025.107057_bib0068","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107057_bib0069","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2025.107057_bib0070","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0071","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1158\/1078-0432.CCR-13-1906","article-title":"Phase I study of Panobinostat plus Everolimus in patients with relapsed or refractory lymphoma","volume":"19","author":"Oki","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0072","doi-asserted-by":"crossref","first-page":"e4832","DOI":"10.1371\/journal.pone.0004832","article-title":"Aberrant epigenetic silencing is triggered by a transient reduction in gene expression","volume":"4","author":"Oyer","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejps.2025.107057_bib0073","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/ijms24054263","article-title":"Histone deacetylases (HDACs): promising biomarkers and potential therapeutic targets in thymic epithelial tumors","volume":"24","author":"Palamaris","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107057_bib0074","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and Belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and Belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0076","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41416-020-0877-8","article-title":"Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma","volume":"123","author":"Pattarawat","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107057_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0078","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107057_bib0079","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor Romidepsin As monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0080","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY. 15 study","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejps.2025.107057_bib0081","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/830260","article-title":"Autophagic and apoptotic effects of HDAC inhibitors on cancer cells","volume":"2011","author":"Rikiishi","year":"2011","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejps.2025.107057_bib0082","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ctrv.2017.03.008","article-title":"Epigenetic therapy and chemosensitization in solid malignancy","volume":"55","author":"Ronnekleiv-Kelly","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2025.107057_bib0083","doi-asserted-by":"crossref","unstructured":"Ruan, J., Zain, J.M., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., Winter, J., Gordon, L.I., Karmali, R., Pro, B., 2021. Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).","DOI":"10.1002\/hon.55_2879"},{"key":"10.1016\/j.ejps.2025.107057_bib0084","doi-asserted-by":"crossref","unstructured":"Sanaei, M., Kavoosi, F., Esmi, Z., 2020. The effect of 5-aza-2\u2032-deoxycytidine in combination to and in comparison with vorinostat on DNA methyltransferases, histone deacetylase 1, glutathione S-transferase 1 and suppressor of cytokine signaling 1 genes expression, cell growth inhibition and apoptotic induction in hepatocellular LCL-PI 11 cell line. Volume 14.","DOI":"10.18502\/ijhoscr.v14i1.2360"},{"key":"10.1016\/j.ejps.2025.107057_bib0085","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.31557\/APJCP.2021.22.7.2089","volume":"22","author":"Sanaei","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ejps.2025.107057_bib0086","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbagrm.2018.01.017","article-title":"Dysregulation of cellular microRNAs by human oncogenic viruses\u2013implications for tumorigenesis","volume":"1861","author":"Santos","year":"2018","journal-title":"Biochim. Biophys. Acta BBA Gene Regul. Mech."},{"key":"10.1016\/j.ejps.2025.107057_bib0087","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/CAD.0000000000000122","article-title":"Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells","volume":"25","author":"Savickiene","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejps.2025.107057_bib0088","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcb.20179","article-title":"Regulation of histone deacetylase activities","volume":"93","author":"Sengupta","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejps.2025.107057_bib0089","article-title":"Immunohistochemical profile of Hodgkin and non-hodgkin lymphoma","volume":"26","author":"Shahid","year":"2016","journal-title":"Hodgkin Lymphoma"},{"key":"10.1016\/j.ejps.2025.107057_bib0090","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.25218","article-title":"Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance","volume":"127","author":"Shao","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107057_bib0091","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s10637-013-9930-2","article-title":"A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors","volume":"31","author":"Sharma","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejps.2025.107057_bib0092","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2015.03.016","article-title":"Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma","volume":"364","author":"Shin","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2025.107057_bib0093","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2217\/fon-2020-0385","article-title":"The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment","volume":"16","author":"Shirbhate","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0094","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/cancers14010087","article-title":"FDA-approved drugs for hematological malignancies\u2013the last decade review","volume":"14","author":"Sochacka-\u0106wik\u0142a","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107057_bib0095","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-10-1893","article-title":"Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and Non-Hodgkin's lymphomas","volume":"17","author":"Stathis","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0096","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/ars.2014.5915","article-title":"Class I HDACs affect DNA replication, repair, and chromatin structure: implications for cancer therapy","volume":"23","author":"Stengel","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ejps.2025.107057_bib0097","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2009.03.016","article-title":"Biomarkers for predicting clinical responses to HDAC inhibitors","volume":"280","author":"Stimson","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2025.107057_bib0098","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3324\/haematol.2019.220012","article-title":"A phase 1 trial of alisertib and romidepsin for relapsed\/refractory aggressive B-cell and T-cell lymphomas","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2025.107057_bib0099","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bbagrm.2014.02.013","article-title":"Chromatin dynamics: interplay between remodeling enzymes and histone modifications","volume":"1839","author":"Swygert","year":"2014","journal-title":"Biochim. Biophys. Acta BBA Gene Regul. Mech."},{"key":"10.1016\/j.ejps.2025.107057_bib0100","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejps.2025.107057_bib0101","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/bcj.2013.68","article-title":"Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Tan","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejps.2025.107057_bib0102","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","article-title":"The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells","volume":"162","author":"Tiffon","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107057_bib0103","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/epi.22674","article-title":"HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance","volume":"7","author":"Van Damme","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.ejps.2025.107057_bib0104","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1083\/jcb.201807037","article-title":"Emerging mechanisms of asymmetric stem cell division","volume":"217","author":"Venkei","year":"2018","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejps.2025.107057_bib0105","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-19-2152","article-title":"Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-cell lymphoma: results of a phase I dose-escalation Study","volume":"26","author":"Vu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejps.2025.107057_bib0107","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0032-1323692","article-title":"Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia","volume":"224","author":"Witt","year":"2012","journal-title":"Klin. P\u00e4diatr."},{"key":"10.1016\/j.ejps.2025.107057_bib0108","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41598-023-50956-x","article-title":"Targeting HDACs for diffuse large B-cell lymphoma therapy","volume":"14","author":"Wu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2025.107057_bib0110","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Xargay-Torrent","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107057_bib0111","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00432-015-2026-y","article-title":"Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents","volume":"142","author":"Xue","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0112","first-page":"469","article-title":"Phase II trial using romidepsin after gemcitabine, dexamethasone, and cisplatin therapy in elderly transplant-ineligible patients with relapsed\/refractory peripheral T-cell lymphoma: study protocol","volume":"73","author":"Yamasaki","year":"2019","journal-title":"Acta Med. Okayama"},{"key":"10.1016\/j.ejps.2025.107057_bib0113","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1263\/jbb.102.323","article-title":"Utilization of Shochu distillery wastewater for production of polyunsaturated fatty acids and xanthophylls using thraustochytrid","volume":"102","author":"Yamasaki","year":"2006","journal-title":"J. Biosci. Bioeng."},{"key":"10.1016\/j.ejps.2025.107057_bib0114","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107057_bib0115","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/leu.2014.241","article-title":"Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model","volume":"29","author":"Yu","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2025.107057_bib0116","doi-asserted-by":"crossref","unstructured":"Yu, V.W.C., Yusuf, R.Z., Oki, T., Wu, J., Saez, B., Wang, X., Cook, C., Baryawno, N., Ziller, M.J., Lee, E., Gu, H., Meissner, A., Lin, C.P., Kharchenko, P.V., Scadden, D.T., 2017. Epigenetic memory underlies cell-autonomous heterogeneous behavior of hematopoietic stem cells.","DOI":"10.1016\/j.cell.2017.02.010"},{"key":"10.1016\/j.ejps.2025.107057_bib0117","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1080\/10428194.2018.1452208","article-title":"Single-agent panobinostat for relapsed\/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi","volume":"59","author":"Zaja","year":"2018","journal-title":"Leuk. Lymphoma"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T06:17:48Z","timestamp":1742365068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":117,"alternative-id":["S0928098725000569"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107057","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107057"}}